Vectura Group plc (OTCMKTS:VEGPF) Short Interest Down 46.7% in March


Share on StockTwits

Vectura Group plc (OTCMKTS:VEGPF) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 2,400 shares, a drop of 46.7% from the March 15th total of 4,500 shares. Based on an average daily trading volume, of 500 shares, the days-to-cover ratio is presently 4.8 days.

Several analysts have recently commented on VEGPF shares. Zacks Investment Research raised shares of Vectura Group from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Tuesday. Peel Hunt downgraded Vectura Group from a “buy” rating to a “hold” rating in a research report on Monday, January 25th. Citigroup lowered Vectura Group from a “buy” rating to a “neutral” rating in a research note on Friday, January 22nd. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Vectura Group in a research note on Friday, March 19th.

VEGPF opened at $1.43 on Friday. The firm has a fifty day moving average price of $1.53 and a 200 day moving average price of $1.48. Vectura Group has a 1 year low of $1.22 and a 1 year high of $1.67. The stock has a market cap of $864.09 million, a P/E ratio of -35.75 and a beta of 0.69. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 1.98.

About Vectura Group

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD.

Recommended Story: How to trade on quiet period expirations

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.